Google Play icon

Researchers develop new strategy to limit side effects of stem cell transplants

Share
Posted August 16, 2016
This news or article is intended for readers with certain scientific or professional knowledge in the field.

Fluorescence microscopy of mouse lymph nodes reveals that treatment with STAR2 (right) increases the number of regulatory T cells, which express a protein called Foxp3 (red).

Scientists in Germany have developed a new approach that may prevent leukemia and lymphoma patients from developing graft-versus-host disease (GvHD) after therapeutic bone marrow transplants. The researchers describe the successful application of their strategy in mice in “Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion,” which will be published online August 15 ahead of issue in The Journal of Experimental Medicine.

Bone marrow transplants can cure types of leukemia and lymphoma because hematopoietic stem cells derived from the donor’s bone marrow can develop into immune cells capable of killing the patient’s tumor cells. But the donor-derived immune cells may also attack the transplant recipient’s healthy tissues, producing the diverse and sometimes severe symptoms of GvHD. One approach to avoiding GvHD is to co-transplant large numbers of regulatory T cells (T reg cells), immune cells that can suppress the donor cells’ effects on healthy tissue while maintaining their ability to kill tumor cells. This approach is challenging, however, because the T reg cells must first be isolated from the donor’s peripheral blood or bone marrow and then cultivated in the laboratory to produce sufficient numbers for transplantation.

A team of researchers led by Andreas Beilhack and Harald Wajant of the University Hospital W?rzburg devised an alternative way to prevent GvHD in mice, developing a protein called STAR2 that can stimulate the formation of the transplant recipient’s own T reg cells in vivo. Pretreating mice with STAR2 protected them from developing GvHD after immune cell transplantation. The donor-derived cells retained their ability to kill the recipient’s lymphoma cells, however.

STAR2 works by specifically binding to a cell surface protein called TNFR2, activating a signaling pathway that increases the number of T reg cells. Beilhack and colleagues found that a slightly modified version of STAR2 has a similar effect on human T reg cells, suggesting that the approach could also prevent GvHD in leukemia and lymphoma patients after bone marrow or hematopoietic stem cell transplants. “Furthermore, this strategy may be beneficial for other pathological settings in which elevated numbers of regulatory T cells are desirable, such as autoimmune diseases and solid organ transplantation,” Beilhack says.

Source: EurekAlert

Featured news from related categories:

Technology Org App
Google Play icon
85,381 science & technology articles

Most Popular Articles

  1. New treatment may reverse celiac disease (October 22, 2019)
  2. "Helical Engine" Proposed by NASA Engineer could Reach 99% the Speed of Light. But could it, really? (October 17, 2019)
  3. New Class of Painkillers Offers all the Benefits of Opioids, Minus the Side Effects and Addictiveness (October 16, 2019)
  4. The World's Energy Storage Powerhouse (November 1, 2019)
  5. Plastic waste may be headed for the microwave (October 18, 2019)

Follow us

Facebook   Twitter   Pinterest   Tumblr   RSS   Newsletter via Email